Pharmaceutical Last week’s news was largely dominated by financial results, with among many others, Swiss pharma giant Novartis pleasing investors, while Celgene and Gilead Sciences disappointed. Also attracting a good deal of attention was MacroGenics lucrative deal with Incyte for cancer drug candidate MGA012, and Novartis gaining breakthrough status for its melanoma drug combination Tafinlar+Mekinist. 29 October 2017